Introduction
Non Hodgkin's lymphomas (NHL), especially follicular lymphoma (FL) and, to a greater extent, diuse large cell lymphomas (DLCL), are often associated with abnormalities of the 3q27 chromosomal region.
These alterations aect the BCL6 (also called LAZ3) gene which is juxtaposed to heterologous promoters, and presumably deregulated, upon translocation into several other loci (Kerckaert et al., 1993; Ye et al., 1993 Ye et al., , 1995 Miki et al., 1994; Chen et al., 1998a; Chaganti et al., 1998) . Subsequent studies have then demonstrated that the breakpoints are clustered within a 5' non coding region (termed MTC for major translocation cluster) around the ®rst exon. Moreover, the same region of BCL6 frequently undergoes small deletions or point mutations in many cases of NHL so that almost all DLCL cases (the most common form of NHL) and about half of FL cases contain structural alteration of the BCL6 5' non coding region (Migliazza et al., 1995; Bernardin et al., 1997; Chaganti et al., 1998) . However, it was recently reported that the point mutations of the BCL6 5' region also occur in normal germinal center B-cell and therefore are not tumor associated, but rather a developmentally regulated event possibly involved in the normal control of BCL6 expression (Shen et al., 1998; Pasqualucci et al., 1998) . Moreover, another breakpoint in the 200 ± 270 kb region upstream from MTC (termed ABR, for alternative breakpoint region) has been recently described, raising the possibility that the alteration of other BCL6 regulatory regions and/or yet unidenti®ed protooncogenes in the 3q27 region may contribute to certain cases of NHL (Chen et al., 1998b) .
The BCL6 gene encodes a 706 amino acid nuclear protein which contains six kruÈ ppel-like zinc ®ngers at its C-terminus and acts as a sequence-speci®c transcriptional repressor. BCL6 harbors two separable transrepressing regions: the ®rst one is the Nterminal and self-interacting domain, termed POZ (or BTB), which is conserved in many metazoan zinc ®nger or actin-binding proteins; the other one encompasses a large central part of the protein and contains a short sequence shared by the BCL6 close relative BAZF (Bardwell and Treisman, 1994; Albagli et al., 1995 Albagli et al., , 1996 Chang et al., 1996; Seyfert et al., 1996; Baron et al., 1997; Okabe et al., 1998) . The center of the latter region is subjected to phosphorylation by MAPK kinase on two nearby sites, an event that triggers the ubiquitin/proteasome dependent degradation of the BCL6 protein Niu et al., 1998) . Very recently, it was further shown that BCL6 interacts with two corepressors, SMRT (or its relative NcoR) and mSIN3A, as well as with a histone deacetylase (HDAC1) suggesting that it may repress transcrip- BCL6fg (LAZfg) or the N-terminally truncated derivative BCL6D1-514fg (Znfg) upon removal of tetracycline. After the selection stably resistant cells were plated at high density in a medium with or without tetracycline (see Materials and methods). Five mg of total RNA were harvested after 48 h, loaded and hybridized with a probe Growth suppression and apoptosis by BCL6 (LAZ3) O Albagli et al tion at least in part by locally inducing a repressive (hypoacetylated) chromatin structure. This mechanism appears to be shared by other POZ/zinc ®nger (POK) transcriptional repressors since PLZF, a relative of BCL6 involved in certain cases of acute promyelocytic leukemia, recruits the same SIN3/ SMRT(NcoR)/HDAC complex and also depends upon HDAC activity to repress transcription (Dhordain et al., 1997; Hong et al., 1997; David et al., 1998; Dhordain et al., 1998; Grignani et al., 1998; Guidez et al., 1998; Lin et al., 1998; Wong and Privalsky, 1998; Huynh and Bardwell, 1998) . BCL6 is expressed in most tissues and in many cell types in vitro (Kerckaert et al., 1993; Fukuda et al., 1995; Allman et al., 1996; Albagli et al., 1998) . In agreement with the frequent incidence of BCL6 alterations in certain lymphomas, BCL6 is an important regulator of lymphoid development. Indeed, it is prominently expressed in B and T cells within the germinal center and is required for the formation of germinal centers. In addition, BCL6 dampens Th2 cell mediated immunity. Finally, it binds the STAT cognate sequences and represses transcription activated by STAT-6, one of the central mediators of IL4-driven Th2 cell dierentiation (Dent et al., 1997; Ye et al., 1997; Fukuda et al., 1997; Huynh and Bardwell, 1998) . Given the mature B cell origin of DLCL, all of these data provide important insights into the understanding of the implication of BCL6 in B-cell malignancies but do not clarify its role at a cellular level. Only correlative studies have suggested contradictory hypotheses regarding the participation of BCL6 in the control of cell growth. Indeed in germinal center (GC), BCL6 appears to be required for the proliferation of B cells while it is expressed by both quiescent and proliferating GC B cells (Cattoretti et al., 1995; Ye et al., 1997) . In in vitro activated by lymphocytes, BCL6 behaves as an immediate early gene but is strongly downregulated before the entry into S phase (Fukuda et al., 1995; Allman et al., 1996) . Finally, in various other cell types, including keratinocytes, myocytes and myeloid cells, the expression of BCL6 increases upon exit from the cell cycle and terminal dierentiation (Yoshida et al., 1996; Yamochi et al., 1997; Albagli et al., 1998) . Thus, the in¯uence of BCL6 on cell proliferation and survival remains largely unknown.
In this study, we used a tetracycline-regulated system to more directly explore how BCL6 could in¯uence cell growth and survival. In human U2OS osteosarcoma cells, forced expression of BCL6 induces both growth suppression correlating with an inecient progression in the S phase of the cell cycle, and apoptosis. Thus BCL6 restricts cell cycle progression and cell survival. Interestingly, overexpressed BCL6 can be colocalized with sites of ongoing DNA synthesis, suggesting that it may directly regulate S phase initiation and/or progression. In contrast, the isolated Zn ®nger region of BCL6, which binds BCL6 cognate target sequence but lacks transcriptional repression activity slows, but does not suppress, the growth of U2OS cells and does not induce apoptosis. Thus, at least in part, the eects of BCL6 overexpression on cell growth and survival may rely on its ability to self interact and/or to recruit its transcriptional corepressors.
Results

Generation of BCL6fg and BCL6D1-514fg inducible cell lines
A tetracycline-regulated system (Gossen and Bujard, 1992) was set up to examine the eects of BCL6 on cell growth and survival. To generate the clones inducible for BCL6 expression, we used the parental U2OS derived clone UTA-6. UTA-6 cells are stably transfected with the tTA chimeric activator which comprises the activation domain of the herpes virus VP16 fused to the E. coli tetracycline repressor. tTA binds the TET operator upon withdrawal of tetracycline from the culture medium (Englert et al., 1995) . The parental UTA-6 cells which express a very low level of endogenous BCL6 mRNA (data not shown) were stably transfected with a construct placing a¯agged version of the human BCL6 cDNA (thereafter referred to as BCL6fg, Dhordain et al., 1995) under the control of the TET operator. Several clones were then selected for further analysis. In two independent clones (see Materials and methods), termed UTA-L1 and UTA-L2 (`L' for LAZ3, the former name of BCL6), the basal (in presence of tetracycline) expression of BCL6fg is very similar to BCL6 endogenous levels while removal of tetracycline leads to an induction of BCL6fg mRNA that is detectable after a few hours (data not shown) and reach several hundred-fold after 48 h (Figure 1a ). This is similar to other inducible clones derived from the UTA-6 parental cells (Englert et al., 1995) . The expression of the BCL6fg protein at the expected size was veri®ed by Western blot while immuno¯uorescence experiments gave a nuclear punctated or speckled pattern very encompassing the 3' coding and non-coding human BCL6 cDNA (see Materials and methods). The same blot was hybridized by a rat ribosomal S26 probe to show RNA loading and integrity. Two clones expressing the BCL6fg mRNA (termed UTA-L1 and UTA-L2) and two clones expressing the Znfg mRNA (termed UTA-Z1 and UTA-Z2) at the expected size in tetracycline (tet) free medium, but not in tetracycline containing medium, were chosen for further analysis. Although only the time 48 h is presented, the induction is detectable as early as a few hours after the removal of tetracycline (data not shown). (b) UTA-L1, UTA-L2, UTA-Z1 and UTA-Z2 cells were plated at high density in tetracycline-free or tetracycline medium and total proteins were harvested after 48 h and quanti®ed. Left: 10 mg of total proteins were analysed by Western blot using the polyclonal C19 anti BCL6 (BCL6) Cterminus antibody. Right: the membrane was stained by Coomassie blue to show the loading and integrity of each sample. (c) UTA-L1 and UTA-Z1 were plated in a tetracycline free medium for 48 h. Left: immuno¯uorescence using the C19 antibody and analysed through conventional microscopy. Similar results were obtained with the M2 (anti-¯ag) monoclonal antibody. No signal could be detected in cells plated in tetracycline-containing medium (not shown). The induced UTA-L2 and UTA-Z2 cells gave a pattern indistinguishable from that obtained in induced UTA-L1 cells and induced UTA-Z1 cells, respectively (not shown). Right: the same cultures were stained with DAPI to visualize the nuclei Huynh and Bardwell, 1998) . Note that in UTA-L1 or UTA-L2 undergoing mitosis, the BCL6fg staining gives a diuse cytoplasmic and nuclear signal superimposed by dots in both compartments (Figure 1c) .
Previous studies have reported that both the POZ domain and the central region between the POZ domain and the zinc ®nger display repressing activity and contribute to the recruitment of the HDACcontaining repressing complex (Albagli et al., 1996; Chang et al., 1996; Baron et al., 1997; Dhordain et al., 1997 Huynh and Bardwell, 1998; Wong and Privalsky, 1998) . Thus, to determine whether the possible eects of BCL6fg on cell proliferation could be correlated with its transcriptional silencing activity, we also isolated UTA-6 cells stably transfected with a truncated version of BCL6 (BCL6D1-514fg, thereafter referred to as Znfg) which codes for an entirē agged-zinc ®nger region of BCL6 but lacks its repressing domains. Two independent clones (see Materials and methods), termed UTA-Z1 and UTA-Z2 showing very high levels of the truncated Znfg derivative in absence of tetracycline and undetectable expression in presence of tetracycline were chosen for further analysis ( Figure 1a ). Note that, in tetracyline free medium, the expression level of the Znfg protein by both UTA-Z clones is similar or even slightly higher than the level of BCL6fg protein in induced UTA-L1 and UTA-L2 cells. This allows the comparison of their eect on cell growth and survival ( Figure 1b , see below). Interestingly, the Znfg derivative is nuclear (Figure 1c ), indicating that the zinc ®nger region contains at least one of the nuclear targeting signals of BCL6. In contrast to full length BCL6fg, Znfg does not produce regular spherical nuclear substructures ( Figure 1c ; Dhordain et al., 1995; Huynh and Bardwell, 1998) , but a diuse nuclear staining sometimes superimposed by irregularly shaped nuclear areas of stronger concentration ( Figure 1c ). As expected, Znfg binds very eciently to the B6BS probe (Chang et al., 1996 ; data not shown) but fails to repress via this sequence ( Figure  2 ). In fact, it acts as a dominant negative version of BCL6 since it partially overcomes the BCL6-mediated transcriptional repression, most likely by competing for the binding to the BCL6-binding site of the reporter plasmid ( Figure 2 ).
BCL6fg expression potently suppresses cell growth
We ®rst investigated the eect of BCL6fg on cell growth. To this end, UTA-L1, UTA-L2 UTA-Z1 and UTA-Z2 cells were plated at low density in presence or absence of tetracycline (see Materials and methods). Under these conditions, induced UTA-Z1 or UTA-Z2 cells grew for the entire length of the experiment, though more slowly compared to the corresponding uninduced cells (Figure 3a and b). In contrast, the induction of BCL6fg expression completely suppressed cell growth in both UTA-L1 and UTA-L2 clones (Figure 3a and b). Though the induced UTA-Z1 and UTA-Z2 cells appear to grow slowly (Figure 3a) , the eciency of cell growth inhibition (measured by ratio of the number of`tet+ cells' versus`tet7 cells' after 6 days) is much lower than in both UTA-L1 and UTA-L2 cells (Figure 3c ). Note that tetracycline itself, even at maximal doses used in our experiments (2 mg/ml) does not aect the growth of the parental UTA-6 cells (data not shown). Moreover, the tetracycline-based system oers the possibility to modulate the strength of the induction by using dierent doses of tetracycline (Gossen and Bujard, 1992) . In our hands and in agreement with previous studies, the expression of the tetracycline-regulated gene is still nearly blocked at 20 ng/ml of tetracycline whereas an almost complete induction is obtained at 2 ng/ml (Gossen and Bujard, 1992 ; data not shown). In UTA-L1 cells, we thus demonstrated that, under equivalent culture conditions, the strength of growth inhibition correlates with the level of BCL6fg induction ( Figure 3d ). We conclude that BCL6fg exerts a dose-dependent antiproliferative eect whose full eciency requires its transcriptional repression domains.
BCL6fg, but not Znfg, triggers apoptosis
To determine the basis of the BCL6fg growth suppressive eect, we ®rst examined whether BCL6fg alters cell growth by inducing cell death. In this regard, we observed that many induced, but not non-induced, UTA-L1 or UTA-L2 cells¯oated after 4 or 5 days in tetracycline-free medium ( Figure  3a and data not shown). Moreover, many of the remaining adherent induced UTA-L1 cells appear to undergo apoptosis (programmed cell death) as they show apoptosis-like blebbing (Figure 4a ). DNA Figure 2 The Znfg derivative does not repress transcription but antagonizes the BCL6-induced transcription. UTA-Z1 cells plated in presence of tetracycline and cotransfected with the BCL6-responsive B6BS-tk-Luc reporter vector together with an expression vector encoding BCL6 (+) or the corresponding empty vector (7). Fifty ng of the pSVbgal vector was added to each transfection mix to correct for variation in transfection eciency (see Materials and methods). The cells were harvested 48 h after transfection and normalized luciferase activities were plotted. Tetracycline was maintained in the culture medium throughout the experiment (+) or removed from the time at which the cells were exposed to the transfection mix (7) staining with DAPI supports this conclusion since many of the UTA-L1 cells grown in tetracycline-free medium, but not in presence of tetracycline, harbor a fragmented or condensed nucleus, two typical features of cell undergoing apoptosis (Figure 4b ). Similar observations were made on UTA-L2 cells (data not shown). Con®rming these observations, staining with propidium iodide and¯ow cytometric analysis on cells plated at high density (see Materials and methods) show a sub G1 peak in induced, but not in non-induced, UTA-L1 cells after 5 days (Figure 5a ). This indicates the presence of a large population of hypodiploid cells (DNA content below the normal G1 complement of 2N), which is a hallmark of apoptosis (Ferrucci et al., 1997) . In the same experiments, a measurement of the size of the Figure 3 BCL6fg is a much more potent growth suppressor than Znfg. (a) UTA-L1, UTA-Z1, UTA-L2, and UTA-Z2 cells were plated at low density in a medium containing (+tet) or not (7tet) tetracycline (see Materials and methods) (day 0). The cells were harvested and counted at the indicated day. Each point represents the mean of triplicate samples. (b) Micrographs of UTA-L1 and UTA-Z2 cell culture after 6 days of culture in tetracycline containing medium (+tet) or in tetracycline-free medium (7tet). UTA-L2 and UTA-Z1 gave results similar to UTA-L1 and UTA-Z2, respectively (not shown). (c) The ratio of the number of cells in tetracycline-containing medium versus the number in tetracycline-free medium after 6 days is plotted for each clone. Despite some clonal variation for cell proliferation in presence of tetracycline, this ratio is similar between UTA-L1 and UTA-L2, and between UTA-Z1 and UTA-Z2. (d) Dose dependence of the BCL6fg-growth suppressive eect. UTA-L1 cells were plated at low density in a medium containing the indicated concentrations of tetracycline. The cells were then harvested after 6 days and counted. Each point represents the mean of triplicate samples cells through forward light scatter indicates that a marked cell shrinkage, which is also a feature of apoptosis, accompanies the death of the UTA-L1 cells (Figure 5b ). Further supporting this view, the UTA-L1 cells undergoing shrinkage correspond to the hypodiploid nuclei (Figure 5b ). Based on all these criteria, we conclude that at least in part, the growth suppressive eect of BCL6fg results from the triggering of apoptosis. Note that the apoptosis is not synchronous in that few apoptotic cells can be found by DAPI staining after 2 ± 3 days of BCL6fg expression (data not shown) while a more prolonged expression (5 ± 6 days) is needed to induce the death of almost the entire culture (Figures 3b and 4b) . In this respect, BCL6-mediated apoptosis resembles that observed upon overexpression of WT-1, another kruÈ ppel-like transcriptional repressor (Englert et al., 1995) . In sharp contrast, despite the negative eect of Znfg on cell growth, UTA-Z1 and UTA-Z2 cells do not appear to undergo apoptosis by any of the criteria described above (Figures 3b, 4b, 5a and b) . Thus, the pro-apoptotic eect of LAZfg is not produced by the high expression of the Znfg mutant indicating that it depends on some functions performed by the N-terminal part of BCL6, presumably its protein/protein interaction and transcriptional regulatory properties.
BCL6fg expression leads to an inecient progression in S phase
Though the growth inhibition mediated by BCL6 is associated with the triggering of apoptosis, we noticed that the number of UTA-L1 cells is clearly reduced by BCL6fg expression as early as 3 days after plating at both low and high density, a time at which few condensed nuclei can be found by DAPI staining (Figure 3a and data not shown) . This suggested that apoptosis may not be entirely responsible for the growth suppression mediated by BCL6fg. Thus, to better understand the early growth suppression by BCL6fg, we examined whether it could also in¯uence cell cycle progression. To this end, we plated UTA-L1 at high density and used¯ow cytometry on cells stained for DNA content with propidium iodide after 72 h in a medium with or without tetracycline. At this time, an alteration of the cell cycle pro®le was observed upon BCL6fg expression in UTA-L1 cells. Indeed, the number of cells in S phase of the cell cycle was signi®cantly increased while the number of cells in G1 was decreased (Figure 6 ). Importantly, this shift is much less marked upon overexpression of the Znfg mutant ( Figure 6 ). This distortion suggests that BCL6fg impairs progression in S phase. To examine this possibility, we synchronized UTA-L1 cells by 48 h exposure to a serum-poor medium (0.5% FCS) followed by 20 h exposure to a serum-rich medium (10% FCS) in presence of 2 mM hydroxyurea. Under these conditions, the UTA-L1 cells tend to accumulate at the G1/S boundary ( Figure 7 ; Bates et al., 1998) and were then released (time`0' ) in a hydoxyurea-free serum-rich medium. Note that tetracycline was withdrawn from the medium of the induced cells at the time of plating in serum-poor medium, so that the timè 0' corresponds to about 3 days with regard to BCL6fg induction in`tet7' UTA-L1 cells (Figure 7a ). We thus observed that UTA-L1 cells cultured in a tetracyclinefree medium are strongly delayed, though not blocked, in their progression throughout S phase, a bias that is most obvious 9 and 12 h after their release from the hydroxyurea block (Figure 7a) . Again, and in agreement with our observation in non-synchronized UTA-Z1 cells (Figure 6 ), the expression of the Znfg mutant has a much weaker eect on the ability of the cells to progress through S phase (Figure 7b ).
Overexpressed BCL6fg can associate with sites of ongoing DNA synthesis That BCL6fg induction impairs progression through S phase could result from an`indirect' role, i.e. the transcriptional silencing by BCL6fg of genes regulating S phase progression, and/or from a direct interference of BCL6fg with DNA replication. Interestingly, the nuclear dots or ring-like structures formed by BCL6fg resemble replication foci (Leonhardt et al., 1992; Cardoso et al., 1993) , raising the possibility that BCL6fg could be indeed present in such nuclear substructures. To test this hypothesis, induced UTA-L1 cells were pulse-labeled with bromodeoxyuridine (BrdU) which stains nuclear sites of ongoing DNA replication. Double-immunofluorescence using either of the two polyclonal anti BCL6 antibodies together with a monoclonal anti BrdU shows colocalization in some UTA-L1 cell nuclei (Figure 8a ± c) suggesting that BCL6fg could associate with replication foci. Though the colocalization is almost complete when observed, some cells, presumably not in S phase, display a punctated BCL6fg pattern without any BrdU staining (not shown). To con®rm this ®nding, we also examined whether LAZfg could also colocalize with Cyclin A (CYC-A), which preferentially accumulates in nuclear sites of DNA synthesis (Cardoso et al., 1993) . In some induced UTA-L1 cells, we also observed colocalization between BCL6 and CYC-A (Figure 8i ± k) . Note, however, that certain nuclei display a dot-like pattern for BCL6fg and a nuclear diuse staining for CYC-A. Altogether, these results indicate that overexpressed BCL6fg can associate with the nuclear sites of ongoing DNA synthesis, suggesting that it may directly aect the onset and/or the progression of replication. In contrast, in agreement with its diuse nuclear localization, the Znfg derivative does not Figure 5 BCL6fg, but not Znfg, expressing cells undergo cell shrinkage correlating with hypodiploidism. (a) UTA-L1 and UTA-Z1 cells were plated at high density in a medium with (+tet) or without (7tet) tetracycline and harvested after 5 days to be propidium iodide labeled and analysed for their DNA content using FACS calibur. (b) Forward light scatter (horizontal axis) and side scatter (vertical axis) analyses of the same cells as in (a). These parameters are related to cell size and granularity, respectively. Note that the cells undergoing shrinkage (SH area), almost only found in induced UTA-L1 cells, correspond to the hypodiploid nuclei DNA content (sub G1) among all cells (tot) Growth suppression and apoptosis by BCL6 (LAZ3) O Albagli et al appear to colocalize with the nuclear sites of DNA replication (Figure 8d ± f) . In some nuclei, we even observe a reciprocal pattern, with the punctated BrdU staining outside the subnuclear areas concentrating Znfg (not shown), suggesting that these may correspond to late replicating condensed chromatin (Lima de Faria and Jaworska, 1968) .
Discussion
The POZ and zinc ®nger (POK) proteins de®ne a family of transcription factors found in both arthropods and vertebrates. Many common biochemical features have been de®ned for this class of proteins, in particular their ability to self aggregate, to heteromerize with related, but distinct, POK proteins, and to interact with multiproteic complexes involved in transcriptional regulation. However, despite the possible implication of several of them, such as BCL6, PLZF, APM-1 and HIC-1, in human neoplasia (Makos-Wales et al., 1995; Reuter et al., 1998 and references therein), little is known about their role in the control of cell growth, dierentiation and survival.
In this study, we were interested in the cellular functions of the BCL6 protooncogene. Using an inducible expression system, we found that BCL6fg almost completely suppresses cell growth and triggers both cell-cycle distortion and apoptosis. The mechanisms of BCL6fg-induced apoptosis remain to be examined, especially whether there could be a causal link between the impairment in cell cycle progression and apoptosis, as in the case of the c-rel protooncogene (Bash et al., 1997) . The fact that UTA-L1 cells expressing BCL6fg hardly progress throughout S phase suggests that BCL6fg negatively regulates DNA replication. Given that BCL6fg acts as a transcriptional repressor, it is possible that it`indirectly' controls S phase progression by reducing the transcription of some genes required to initiate and/or complete DNA synthesis. In this regard, it may be relevant that BCL6 could overcome certain regulatory pathways, for instance those mediated by the STAT transcriptional activators (Dent et al., 1997) . As the Znfg is likely tò passively' occupy BCL6/STAT cognate sequences (i.e. binding without active transcriptional repression), it may also, though more weakly, attenuate these pathways and hence exert the mild growth inhibition we observe in induced UTA-Z clones. However, an additional more direct implication of BCL6fg in DNA replication is suggested by the association of overexpressed BCL6fg with nuclear sites of ongoing DNA synthesis (Figure 8 ). Since Znfg is not recruited on sites of BrdU incorporation, it is likely that the colocalization between BCL6fg and replication foci entails protein/protein interactions through the POZ domain and/or the central region. Replication involves several enzymes that covalently modify the DNA and histones Figure 6 Alteration of cell cycle upon LAZfg induction. UTA-L1 and UTA-Z1 cells were plated at high density in a medium with (+tet), or without (7tet) tetracycline and harvested after 72 h to be propidium iodide labeled and analysed for their DNA content using FACS calibur. The percentage of cells in each phase is indicated below each diagram to ensure chromatin assembly and possibly transcriptional pattern memory (Leonhardt et al., 1992; reviewed in Roth and Allis (1996) . Among these enzymes, HDAC1, which may remove certain acetyl moieties from newly synthetized histones after their assemblage with replicating DNA (Roth and Allis, 1996) , could attract BCL6fg to replication foci (David et al., 1998; Dhordain et al., 1998) . Assuming that the overexpressed BCL6fg mimics the role of endogenous BCL6, this opens the possibility that BCL6 restricts cell growth and impairs cell-cycle progression by targeting HDAC1, both as transcriptional corepressor and as sequestered' partner required in S phase, much as recently proposed to explain, in part, the antiproliferative eect of RB (Roth and Allis, 1996; MagnaghiJaulin et al., 1998) . Alternatively, it remains conceivable that the reduced G1 population and impaired progression during S phase upon BCL6fg induction re¯ect an inhibition of endogenous BCL6 function, possibly because of aberrant self-aggregation and/or titration of BCL6 partners. In this case, endogenous BCL6 may be required to maintain U2OS cells in G1 and/or to progress during S phase. Note, however, that a positive role for BCL6 in progression during S phase is dicult to reconcile with the observations that BCL6 expression strongly decreases before cells enter S phase in B and T cells and increases when keratinocytes and myocytes undergo permanent exit from the cell cycle and terminal dierentiation Yoshida et al., 1996; Yamochi et al., 1997; .
Forced expression of several vertebrate POK proteins inhibits cell proliferation and/or survival, suggesting that they are a novel family of growth suppressors (Makos-Wales et al., 1995; Numoto et al., 1995; Peukert et al., 1997; Reuter et al., 1998, this work) . Likewise, at least for the c-MYC partner MIZ-1, the suppression of cell growth also correlates with an accumulation in S phase (Peukert et al., 1997) . However all these studies are based on constitutive transient or stable overexpression, while we used a tetracycline inducible system which shows almost no leakiness in presence of tetracycline and demonstrates a clear dose-dependent growth suppression by BCL6fg. Moreover, we also expressed at similar levels a truncated BCL6 derivative unable to repress transcription and ®nd that it slows, but does not suppress, cell growth, is much less ecient at delaying S phase progression and fails to induce apoptosis. This indicates that, for a large part, the observed eects of BCL6fg on cell growth and survival are not nonspeci®c eects due to vast overexpression but rather rely on its ability to engage protein/protein interaction, most likely with itself and its corepressors. (a) UTA-L1 cells were plated at high density in a medium with (+tet), or without (7tet) tetracycline and synchronized at G1/S boundary upon exposure to low serum followed by a hydroxyurea block as described in Materials and methods. Just before the release from the hydroxyurea block (time 0), and then at the indicated times the cells were harvested, stained with propidium iodide and analysed for DNA content by FACS calibur. (b) UTA-Z2 cells were submitted to the same experiment. Only the times 0 and 12 h are presented While this work was being completed, the cellular role of PLZF, another oncogenic POK protein, was being investigated in detail by in vitro retroviral infection of 32Dc13 myeloid cells (Shaknovich et al., 1998) . The observed eects show similarities with those reported here. In 32Dc13 cells PLZF also acts as a potent growth suppressor, in part by inducing the secretion of yet unknown growth inhibitory factor(s), and augments spontaneous apoptosis. However, PLZF overexpression arrests the cell in G1 rather than in S phase. Though possibly pointing out a functional specialization between these two highly related POK proteins, this dierence may also re¯ect, in part, the chosen experimental conditions. For instance, the eects of PLZF were analysed in selected populations which therefore express PLZF at a level compatible with long-term survival (Shaknovich et al., 1998) while UTA-L1 and UTA-L2 cells exposed to a tetracyclinefree medium abruptly express very high level of BCL6fg and died after a few days. Finally, it is of note that PLZF exerts an ambivalent role on apoptosis as it partially protects 32Dc13 cells against the apoptosis triggered by IL3 withdrawal. Whether BCL6fg expressing cells would escape some apoptosic signals remains to be investigated.
More generally, transcriptional repressors recruiting histone deacetylase repressing complex are often growth suppressors (see Walsh and Perlman, 1997; Figure 8 Overexpressed BCL6fg can localize to nuclear sites of ongoing DNA synthesis. UTA-L1 (a ± c, and g ± i) or UTA-Z1 cells (d ± f) were induced for 48 h to express BCL6fg or Znfg, respectively. (a ± c) Induced UTA-L1 cells were pulse-labeled with bromodeoxyuridine (BrdU) just before ®xation. The cells were then sequentially labeled to detect both BCL6fg using the rabbit N3 anti-BCL6 antibody (red, a) and BrdU using the BMG 6H8 monoclonal anti-BrdU antibody (green, b) and subjected to confocal microscopy. The overlay shows the colocalization of both stainings (orange, c). Similar results were obtained when the rabbit C19 anti-BCL6 antibody was used to detect BCL6fg (not shown). (d ± f) Induced UTA-Z1 were submitted to the same experiment except that the rabbit C19 anti-BCL6 antibody was used to detect Znfg. The diuse Znfg staining (red, d) does not colocalize with the punctate BrdU staining (green, e) (overlay, f). (g ± i) Induced UTA-L1 cells were subjected to double immuno¯uorescence labeling followed by confocal microscopy to detect both BCL6fg (red, g) and endogenous Cyclin A (CYC-A) (green, h) using, respectively, the monoclonal M2 anti-¯ag antibody and an anity puri®ed rabbit anti CYC-A antibody. The overlay shows the colocalization of both stainings (i, orange) . Note that the diuse nuclear BCL6fg staining (visible on Figures 1c and Figure 8a ), but not the nuclear dots, largely disappears upon the`pre-permeabilization' procedure (before formalin ®xation) used in this experiment (see Materials and methods) Growth suppression and apoptosis by BCL6 (LAZ3) O Albagli et al Albagli et al., 1998; Foley et al., 1998 and references therein) . Of particular interest is the case of RB, which inhibits both the entry and the progression through S phase (Brehm et al., 1998; Chew et al., 1998; Knudsen et al., 1998; Luo et al., 1998; MagnaghiJaulin et al., 1998 and references therein) . On the contrary, certain histone acetyltransferases may facilitate the progression in the cell cycle, as P300 undergoes an activating phosphorylation at the G1/S boundary (Ait-Si-Ali et al., 1998) while mice lacking P300 have defects in cell proliferation (Yao et al., 1998) . However, inactivation of p300 in mice or in C. elegans also impairs certain dierentiation processes, suggesting that it is not exclusively dedicated to cell proliferation (Yao et al., 1998; Shi and Mello, 1998) . What could be learned from our work regarding the involvement of BCL6 in non-Hodgkin lymphomas (NHL)? BCL6 expression appears tightly regulated throughout B cells dierentiation, as its transcription culminates in mature B cells from the germinal centers while it decreases upon terminal dierentiation in plasma cells (Cattoretti et al., 1995; Ye et al., 1995; Chen et al., 1998a) . It has been proposed that BCL6 acts as an oncogene whose rearrangement in NHL leads to its overexpression in late stages of B cell dierentiation because of fusion to the regulatory regions of its translocation partners Chen et al., 1998a) . Accordingly, the expression pattern of dierent translocation partners has suggested they may drive an abnormally persistent expression of BCL6 throughout B cell dierentiation (Chen et al., 1998a) . Moreover, in one case of NHL, the BCL6 allele translocated into the IgH gene, but not thè normal' one, is transcribed . However, in the latter case, it is not clear whether the`normal' allele, presumed to be expressed at normal levels, has not undergone`submicroscopic' alteration(s). In fact, no clear BCL6 overexpression in NHL harboring BCL6 rearrangements has been evidenced to date (Ohno and Fukuhara, 1997) . Following our data, it appears rather that BCL6 potently restricts cell growth. Thus, BCL6, like certain other nuclear proteins involved in hematopoietic malignancies such as PML, may be a tumor-suppressor that somehow undergoes loss of function upon structural alterations (Quignon et al., 1998; Wang et al., 1998) . This hypothesis ®ts better with the often biallelic nature of the BCL6 alterations (Migliazza et al., 1995) and is not incompatible with the promoter substitution model if it leads to an aberrantly low expression of BCL6 at (a) critical step(s) of the cell cycle. Interestingly, similar hypotheses have been raised for the POK protein PLZF, which may be functionally inactivated upon its reciprocal translocation with RARa, as well as for APM-1 whose biallelic inactivation may be relevant in HPV-induced cervical tumor (Shaknovich et al., 1998; Reuter et al., 1998) .
Materials and methods
Plasmids
All plasmids were prepared by Qiagen technology. Cloning and sequencing were performed following standard procedures. An entire BCL6fg cDNA or the cDNA encoding a D1 ± 514 derivative was inserted in the tetracycline-regulatable pUDH 10-3 vector (Gossen and Bujard, 1992) to generate pUDH10-3-BCL6fg or pUDH10-3-Znfg, respectively. Details regarding these constructions as well as regarding the cotransfected resistance vector (either pBABE-puro or pGK-hygro) are available upon request.
Cell culture, transfections and generation of BCL6fg and Znfg inducible clones
The U2OS-derived parental UTA-6 clone has been previously described (Englert et al., 1995) and was routinely maintained in Dulbecco medium supplemented with 10% fetal calf serum (Boehringer) (thereafter referred to as DF10), G418 (GIBCO ± BRL) 500 mg/ml and tetracycline (Sigma) 2 mg/ ml. It constitutively expresses the TET-VP16 inducible transactivator (Gossen and Bujard, 1992) . To generate UTA-L1 and UTA-Z1 clones, UTA-6 cells were plated at 50 ± 80% con¯uency in 3.5 cm dishes and co-transfected in presence of tretracycline with (per dish) pBABE-puro (50 mg) along with either linearized pUDH10-3-BCL6fg (1 mg) or linearized pUDH10-3-Znfg using 8 ml of lipofectamine reagent (Boehringer). After 24 h, the cells of one dish were plated in three 10-cm dishes in the selection-medium (DF10 plus G418 500 mg/ml, tetracycline (Sigma) 2 mg/ml and puromycine (Sigma) 1 mg/ml (Englert et al., 1995) . Resistant clones were picked up and analysed for BCL6fg inducible expression by immuno¯uorescence. UTA-L1 and UTA-Z1 cells were then maintained in the selection medium. To obtain both UTA-L2 and UTA-Z2 clones, the same procedure was followed except that pBABE-puro was replaced by pGK-hygro (a generous gift of Patrick Martin, CNRS Orsay, France), and the transfected cells were then selected in DF10 plus G418 500 mg/ml, tetracycline 2 mg/ml and hygromycine 150 mg/ml (Boehringer). Note that UTA-L1 and UTA-L2 clones on one hand, and UTA-Z1 and UTA-Z2 clones on the other hand are two pairs of independent clones as they were obtained from two dierent transfection/ selection procedures using a dierent selective drug.
The transient transfection in UTA-Z1 cells were performed in the same conditions and with a mixture of 200 ng of the B6BS-tk-luc reporter (Chang et al., 1996) , 50 ng of the pSVbgal vector used to correct for dierences in transfection eciency and 800 ng of either the pcDNA3-BCL6fg or the corresponding empty vecotr. b-gal and luciferase activities were determined as described previously (Dhordain et al., 1997) .
To eciently remove tetracycline, the cells to be induced were trypsinized, washed and centrifugated two times and directly plated in DF10 without tetracycline at low density (*10 3 cells/cm 2 ) or high density (*8610 3 cells/cm 2 ) as stated in the text. For all cultures, including the experiments shown, the medium was replaced at least every 4 days by fresh medium containing (or not) tetracycline to maintain the concentration of tetracycline.
Northern blot
Total mRNA were prepared by the High Pure RNA Isolation Kit (Boehringer) according to the instructions of the supplier. Norther blots were then performed as previously described . The probe used to detect the induced mRNA in all clones was a EcoRI fragment encompassing most of the zinc ®nger region and the 3' non-coding of the human BCL6 mRNA (Kerckaert et al., 1993) .
Western blot
UTA-L and UTA-Z cells were plated in DF10 with or without tetracycline at low density. Two days later, the cells were harvested in PBS and an aliquot was kept to quantify each sample by Bio-Rad protein assays. The remaining cells were lysed in buer and 10 mg of total protein were analysed through SDS ± PAGE. The gel was then transferred by elctroblotting (Millipore) on a nitrocellulose membrane (Millipore) and all the subsequent procedures were performed at room temperature. The membrane was saturated with blocking buer 2 h (5% non fat powdered milk; 0.01% gelatine; 1% BSA; 0.02% Tween 20 in TBS 16; TBS 206: Tris 1 M; NaCl 3 M; pH 7.4) then incubated 2 h with a 1/100 e dilution of the puri®ed rabbit anti-BCL6 C19 antibody (100 mg/ml) (Santa Cruz) in the same buer, washed fourfold in TBS/0.02% Tween 20 (TTBS), incubated for 2 h with a 1/20000 e dilution of a horseradish peroxydase conjugated anti-rabbit antibody (Amersham) in blocking buer, washed four times in TTBS. The signals were then revealed using the Western blot Chemiluminescence Reagent (NEN) according to the instructions of the supplier.
Immuno¯uorescence
Immuno¯uorescence experiments were performed as previously described . Similar results were obtained using the C19 anity-puri®ed polyclonal rabbit anti-BCL6 antibodies (Santa Cruz) (1/100 e ), monoclonal M2 (Kodak) (1/400 e ) or, for the UTA-L clones, the N3 anitypuri®ed polyclonal rabbit anti-BCL6 (Santa Cruz) (1/100 e ). These antibodies were revealed by a donkey anti-rabbit Texas red-conjugated antibody (Amersham) (1/100 e ) for the C19 and N3, and by a sheep anti-mouse Texas red-conjugated antibody (Amersham) (1/100 e ) for the M2. For staining with DAPI, the cells were ®xed and permeabilized under the same conditions and incubated in a solution of DAPI (10 ng/ml) in PBS.
For costaining BCL6fg/BrdU and Znfg/BrdU, UTA-L1 and UTA-Zn1 cells were induced for 48 h to express BCL6fg or Znfg respectively and pulse labeled with BrdU for 2 h before ®xation in formalin. The subsequent procedures were performed essentially as previously described : the C19 or N3 antibody was detected with a donkey anti-rabbit Texas red-conjugated antibody (Amersham) (1/100 e ), then the dishes were ®xed again in formalin, rinsed three times in PBS, treated with HCL 4N for 15 min at room temperature, rinsed three times in PBS, and subjected to BrdU detection using the BrdU labeling and detection kit (Boerhinger) according to the recommendations of the manufacturer. In UTA-L1 cells, similar results were obtained whether the N3 or the C19 anti-BCL6 was used. For containing BCL6fg and endogenous Cyclin A (CYC-A) in induced UTA-L1 cells, the M2 monoclonal antibody (1/400 e ) was used together with a puri®ed polyclonal anti-cyclin A antibody (1/100 e ) (Cardoso et al., 1993 , generously provided by Anne Fernandez, CNRS, Montpellier, France). Then, the M2 and anti CYC-A antibodies were detected using a sheep anti-mouse Texas red-conjugated antibody (Amersham) (1/ 100 e ) and a donkey anti-rabbit¯uoresceine-conjugated antibody (Amersham) (1/100 e ), respectively. To better visualize cyclin A in replication foci, ®xation and permeabilization of the cells were performed according to Cardoso et al. (1993) . For both BCL6fg/BrdU and BCL6fg/CYC-A costainings, confocal microscopy (Leica) was used to precisely visualize the colocalization.
Cell cycle analysis
After the indicated times in the appropriate medium (see text), the cells were trypsinized and ®xed in ice-cold ethanol 70% for at least 24 h prior to centrifugation for 4 min at 2000 r.p.m. and resuspended in PBS at about 10 6 cells/ml. RNAse A and propidium iodide were added to a ®nal concentration of 1 mg/ml and 10 mM, respectively, and the cells were incubated for 1 h at room temperature before analysis on FACS calibur (Becton Dickinson). 10 000 events were analysed for each sample. To synchronized U2OS derived clones, the cells were plated at high density in a serum poor medium (0.5% FCS) for 48 h, then refed with a serum rich medium (10% FCS) for 20 h in presence of hydroxyurea (2 mM) to block them at the G1/S boundary (Bates et al., 1998) .
